

AGENDA

 Porta Vittoria

 Porta Ticinese

Track on PEPTIDES

Tuesday, June 28		Wednesday, June 29	
9:00 - 9:15	Welcome	9:00 - 9:15	Welcome
9:15 - 9:55	New Tricks for Solid-Phase Peptide Synthesis Fernando Albericio - <i>University of Barcelona</i>	9:15 - 10:00	Synthetic Virus-Like Particles and Protein Epitope Mimetics in Vaccine Design Javier Rodriguez Balboa - <i>Virometix</i> Lilli Stergiou - <i>Virometix</i>
9:55 - 10:25	Strategies for side reactions & impurity control in therapeutic peptide chemistry Antonio Ricci - <i>Fresenius Kabi iPSUM</i>	10:00 - 10:30	Applying Reinforcement Learning for Peptide Discovery: Theory and Current Implementation in the COVID19 Pandemic Amit Michaeli - <i>Pepticom</i>
10:25 - 10:45	Exploration of PAT & Continuous Flow Applications in Peptide Synthesis Eike-Fabian Sachs - <i>Corden Pharma</i>	10:30 - 11:0	Modern peptide synthesis – Applying real-time monitoring to improve synthesis' efficiency Victoire Laude - <i>Vapourtec</i>
10:45 - 11:40	COFFEE BREAK & EXHIBITION	11:00 - 11:40	COFFEE BREAK & EXHIBITION
11:40 - 12:20	Boosting the downstream processing of therapeutic peptides by means of multicolumn continuous chromatography Martina Catani - <i>University of Ferrara</i>	11:40 - 12:20	Peptide-Based Functional Coatings for Sterile Surfaces Meital Rechtes - <i>Hebrew University of Jerusalem</i>
12:20 - 12:40	IEX resins for peptide purification in an orthogonal system: a case study Alessandra Basso - <i>Purolite</i>	12:20 - 12:50	Silylated peptides: versatile building blocks for biomaterials Cécile Echaliér - <i>Université de Montpellier</i>
12:40 - 13:10	Developing peptide drugs faster with the Peptide Easy Clean (PEC) technology Dominik Sarma - <i>Belyntic</i>	12:50 - 13:10	From Small to Large Scale:Optimizing and upscaling the synthesis ofmelanotan II (MT-II) -Melanocortin Receptor Agonist,on PurePep®Chorus and PurePep®Sonata+ Luisa Aguiar - <i>Gyros Protein</i>
13:10 - 14:20	LUNCH & EXHIBITION	13:10 - 14:20	LUNCH & EXHIBITION
14:20 - 15:00	Engineering of endogenous peptides for methabolic diseases Lars Linderöth - <i>Novo Nordisk</i>	14:20 - 14:50	Solid-Phase Photochemical Modification of Lysine in Peptides Anais F. M. Noisier - <i>AstraZeneca</i>
15:00 - 15:30	Enter the tubes: heterochiral dipeptides' self-assembly into water channels Silvia Marchesan - <i>University of Trieste</i>	14:50 - 15:10	The Future of Commercial Scale Solid Phase Peptide Synthesis: Temperature Modifications for High Purity and Yield Dario Slavazza - <i>CSBio</i>
15:30 - 16:00	Case Study of a Peptide Therapeutic in Rare-Orphan Diseases: Davunetide twenty years later Bruce Morimoto - <i>Alto Neuroscience</i>	15:10 - 15:30	Innovation in peptide development and manufacturing: bringing new concepts into practice Olivier Ludemann-Hombourger - <i>PolyPeptide Group</i>
16:00 - 16:40	COFFEE BREAK & EXHIBITION	15:30 - 16:00	Peptide API Manufacturing through A Minimal-Protection/Green Chemistry Strategy Yi Yang - <i>Ferring Pharmaceuticals</i>
16:40 - 17:20	Peptides in cosmetics: Old hat or Starburst of innovation? Karl Lintner - <i>KAL'IDEES</i>	16:00 - 16:30	Take home messages
17:20 - 17:50	Engineered peptides - a new modality in crop protection Fides Benfatti - <i>Syngenta Crop Protection</i>		
20:00 - 23:00	Business NETWORKING dinner		

Track on OLIGOS

Tuesday, June 28		Wednesday, June 29	
9:00 - 9:15	Welcome	9:00 - 9:15	Welcome
9:15 - 9:55	Towards efficient delivery of therapeutic LNA oligonucleotides Jesper Wengel - <i>University of Southern Denmark</i>	9:15 - 9:55	Cell-penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model Monica Nizzardo - <i>University of Milano</i>
9:55 - 10:25	G-quadruplex forming aptamers as potential therapeutic agents Domenica Musumeci - <i>University of Naples Federico II</i>	9:55 - 10:25	Supporting mRNA-LNP Drug Products from Early R&D Programs to the Market – Scale Up and Production of mRNA key lipids Matthieu Giraud - <i>CordenPharma</i>
10:25 - 10:45	Purification and analysis of exceptional oligos – a case study Patrick Endres - <i>Tosoh Bioscience</i>	10:25 - 10:45	Chromatography challenges to purify Oligonucleotides and mRNA: how to deal with aggressive buffer and high temperature? Jérôme Chevalier - <i>Sartorius Chromatography Equipment</i>
10:45 - 11:40	COFFEE BREAK & EXHIBITION	10:45 - 11:40	COFFEE BREAK & EXHIBITION
11:40 - 12:10	Oligonucleotide Manufacture in Liquid Phase by Nanostar Sieving Piers Gaffney - <i>Exactmer</i>	11:40 - 12:20	Regulatory CMC Interactions and Intelligence for Development and Late Phase ASO Programs Tracey Burr - <i>IONIS</i>
12:10 - 12:30	Sub-ng/mL quantification of antisense oligonucleotides in rat plasma using trap-and-elute microflow LC” Ferran Sanchez - <i>SCIEX</i>	12:20 - 12:40	Towards ton scale manufacturing of oligonucleotides Sven Warhaut - <i>Biospring</i>
12:30 - 13:00	Challenges of Large-Scale Manufacturing of Modified Amidites for Therapeutic Oligonucleotides Yogesh Sanghvi - <i>Rasayan</i>	12:40 - 13:10	CMC Strategies to Assure Quality While Accelerating Development of Oligonucleotides Judy Carmody - <i>Carmody Quality Solutions</i>
13:00 - 14:20	LUNCH & EXHIBITION	13:10 - 14:20	LUNCH & EXHIBITION
14:20 - 15:00	Lipid- and Peptide-Oligonucleotide Conjugates. An historical Perspective Ramon Eritja - <i>IQAC-CSIC</i>	14:20 - 14:50	OLIGOFASTX the end-to-end shuttle for the development of oligonucleotide-based therapeutics for the treatment of rare diseases. Tamara Martinez - <i>Sylentis</i>
15:00 - 15:20	Purification of synthetic oligonucleotides using continuous chromatography (MCSGP) Ralf Eisenhuth - <i>Bachem</i>	14:50 - 15:20	ApTOLL, a promising therapeutic aptamer for the treatment of TLR4-mediated diseases David Pineiro - <i>AptaTargets</i>
15:20 - 16:00	Preclinical development of an antimiR-based drug to treat Myotonic Dystrophy disease Beatriz Llamusi - <i>Arthex Biotech</i>	15:20 - 15:50	CMC Control Strategy for Impurities in Oligonucleotide Synthesis Thomas Rupp - <i>LGC / Thomas Rupp Consulting</i>
16:00 - 16:40	COFFEE BREAK & EXHIBITION	15:50 - 16:40	Take home messages
16:40 - 17:00	Oligonucleotide Manufacture from Development to Large-Scale Peter Rosyk - <i>Asymchem</i>		
17:00 - 17:30	Non-coding RNA-targeted Therapeutics: Pre-Clinical and Clinical Development for Cardiovascular Diseases Janika Viereck - <i>Cardior Pharmaceuticals</i>		
17:30 - 17:50	Boosting a process with digital tools: purification of oligonucleotides by ion exchange Agnès Corbin - <i>Ypso-Facto</i>		
20:00 - 23:00	Business NETWORKING dinner		